GLP-1s at the Pharmacy – A Lens on Consumer-Driven Retail Health (with Hims & Hers stock price update)
By Jane Sarasohn-Kahn on 20 February 2025 in Aging, Boomers, Cardiovascular health, Chronic disease, Consumer experience, Consumer-directed health, Demographics and health, Design and health, Determinants of health, Diabetes, Diet and health, Digital health, Doctors, DTC health, Financial toxicity, Food and health, Food as medicine, GLP-1s, Grocery stores, Health access, Health at home, Health care industry, Health care marketing, Health Consumers, Health ecosystem, Health education, Health engagement, Health marketing, Health media, Health reform, Health regulation, Health social networks, HealthDIY, Heart disease, Heart health, Home health, Inflation Reduction Act IRA, media and health, medical home, Medicare, Medicines, Moms and health, Nutrition, Obesity, Out of pocket costs, Patient engagement, Patient experience, Personal health finance, Pharmaceutical, Pharmacists, Pharmacy, Physicians, Popular culture and health, Prescription drugs, Retail health, SDoH, Self-care, Seniors and health, Shared decision making, Shopping and health, Social determinants of health, Social networks and health, Specialty drugs, Telehealth, Transparency, Trust, User experience UX, Women and health

The nature of retail pharmacy is changing, with both threats and opportunities re-shaping the business itself, and the pharmacy’s role in the larger health/care ecosystem. To keep sharp on the topics, I attended Rx Market Insights: Performance Trends and Outlook for 2025, a data-rich session presented on February 18 by IQVIA and sponsored by Ascend Laboratories. The webinar was hosted by DSN (Drug Store News), appropriately so because the action-packed hour went into detail providing the current state of prescription drugs and the pharmacy in America. Doug Long, IQVIA’s VP of Industry Relations, and Scott Biggs, the company’s Director of Supplier